Welcome to The Five Under 5, your go-to roundup of the top 5 videos of the week.
These short videos are designed for busy oncologists to view on the go, and feature expert insights on breaking news, regulatory updates, practice-changing data shared at medical meetings, and other key topics in the realm of oncology.
Here’s what you may have missed:
Efficacy of Avutometinib Plus Defactinib in Gynecologic Mesonephric Cancer: Rachel N. Grisham, MD
Rachel N. Grisham, MD, of Memorial Sloan Kettering Cancer Center, discusses interim results from a phase 2 study (NCT05787561), which evaluated avutometinib (VS-6766) plus defactinib (VS-6063) in patients with advanced or recurrent gynecologic mesonephric cancer. The threshold of response was exceeded with the combination, which will allow for the opening of stage 2 of the study. Moreover, a reduction in target lesions was observed in all patients. Check out more coverage from the 2025 SGO Annual Meeting on Women's Cancers.
Inclusion Criteria for a Study Evaluating Ide-Cel in Myeloma After Suboptimal Transplant/Maintenance Response: Alfred L. Garfall, MD
Alfred L. Garfall, MD, of Perelman School of Medicine at the University of Pennsylvania, outlines the eligibility criteria for the phase 2 BMT CTN 1902 trial (NCT05032820), which included patients with multiple myeloma who had an incomplete response to first-line therapy, underwent autologous stem cell transplant, and received at least 3 months of maintenance therapy. Patients were pretreated with intensive frontline therapies but still exhibited minimal residual disease before enrollment. The study evaluated lymphodepleting chemotherapy with fludarabine and cyclophosphamide, followed by CAR T-cell therapy using idecabtagene vicleucel (Abecma), with lenalidomide (Revlimid) maintenance quickly resumed afterward. Results from the 2025 Transplant and Cellular Therapy Meetings showed that 63% of evaluable patients achieved a complete response (CR) within 6 months, despite 40% having only a partial response after transplant.
Early Efficacy Data With Nadofaragene Firadenovec in BCG-Unresponsive NMIBC: Jacob Moyer, BS
Jacob Moyer, BS, of Mayo Clinic, presents real-world data supporting the efficacy and safety of nadofaragene firadenovec-vncg (Adstiladrin) in patients with Bacillus Calmette-Guérin–unresponsive non–muscle-invasive bladder cancer, showing a 95% cystectomy-free survival rate at a median follow-up of 8.2 months. Among patients with carcinoma in situ, 79% achieved a CR at 3 months, with 84% maintaining responses at a median follow-up of 7.3 months. Recurrence-free survival rates at 6 and 9 months varied by subgroup, with the overall efficacy-evaluable population showing rates of 66% and 51%, respectively. Adverse effects were mostly low grade, with no grade 4 or 5 events, and common toxicities included bladder spasm (61%), urgency (20%), and fatigue (13%). This video is part of an OncClub package.
Influence of MPN Risk Stratification on Treatment Decision-Making: Seema A. Bhat, MD
Seema A. Bhat, MD, of The Ohio State University Comprehensive Cancer Center—James, emphasizes the importance of risk stratification in guiding treatment decisions for patients with myeloproliferative neoplasms (MPNs), with low-risk patients being managed for symptoms and high-risk patients considered for cytoreductive or targeted therapies. The revised IPSET Thrombosis Score helps stratify essential thrombocythemia and polycythemia vera risk is determined by age and thrombosis history. Allogeneic stem cell transplantation may be a curative option for very high-risk MPNs. Additionally, 4 FDA-approved JAK inhibitors—ruxolitinib (Jakafi), fedratinib (Inrebic), pacritinib (Vonjo), and momelotinib (Ojjaara)—offer targeted treatment for intermediate- and high-risk myelofibrosis, with specific indications based on disease characteristics.
Comparative Efficacy of ARPIs Regardless of Disease Volume or Timing of Metastases in mHSPC: Alan H. Bryce, MD
Alan H. Bryce, MD, of City of Hope Cancer Center, discusses a systematic review of phase 3 trials comparing androgen receptor pathway inhibitors (ARPIs) in metastatic hormone-sensitive prostate cancer (mHSPC), showing largely similar efficacy across abiraterone acetate (Zytiga), apalutamide (Erleada), darolutamide (Nubeqa), and enzalutamide (Xtandi). No significant differences were found in radiographic progression-free survival based on disease volume or metastatic timing, and darolutamide did not demonstrate superiority over other ARPIs. Although enzalutamide may offer a slight advantage over abiraterone plus prednisone in low-volume or de novo metastatic disease, the difference is minimal. Given comparable efficacy between the agents, treatment decisions should prioritize factors such as toxicity profiles, cost, and patient-specific considerations.
For more insights from interviews with key opinion leaders in the oncology field, check out our recent OncLive TV segments. Rather listen to expert interviews on important topics in the space? Check out OncLive On Air.